Doxepin intranasal - Winston Pharmaceuticals

Drug Profile

Doxepin intranasal - Winston Pharmaceuticals

Alternative Names: Dolorac

Latest Information Update: 08 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Winston Pharmaceuticals
  • Class Antipruritics; Dibenzoxepins; Oxepins; Sleep disorder therapies; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Histamine H1 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Headache

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Aug 2015 Phase II development is ongoing in the USA
  • 23 Nov 2010 Final efficacy data from a phase IIa trial in Headache released by Winston Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top